Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Looking forward to EHA 2021

Steven Treon • 1 Jun 2021
EHA 2021
General Antibodies Rituximab Zanubrutinib

Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, highlights key abstracts being presented at EHA 2021, including an abstract comparing zanabrutinib to matched controls. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Steven Treon, MD, PhD, has received research funding and consulting fees from Abbvie/Pharmacyclics, Janssen, Beigene, Eli Lilly and X4.

More from Steven Treon

1:59
Updates in the response criteria for Waldenström’s macroglobulinemia
Steven Treon • 29 Sep 2023
2:23
Practical considerations when treating patients with WM: exciting agents & combinations
Steven Treon • 29 Sep 2023
1:54
Selecting the correct BTK inhibitor for patients with WM: lessons learned from the ASPEN trial
Steven Treon • 29 Sep 2023
1:47
Exciting updates in Waldenström’s macroglobulinemia: the value of BTK inhibitors
Steven Treon • 29 Sep 2023

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals